Additionally, activation of the S6K1 kinase has been detected in over 10% of ER+ breast cancer patients, and several studies suggest that elevated S6K1 levels contribute to palbociclib resistance by activating c-Myc signaling, as observed in both experimental models and patient-derived breast cancer samples [101]. Here, RPS6KB1 is linked to breast carcinoma.